SCHEMBL5456065

SCHEMBL5456065

Cc1cccc(CNC(=O)Nc2sc3c(c2C(N)=O)CCOC3)c1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.56
FLT3 P36888 2/20 0.49
ANO1 Q5XXA6 3/20 0.46
USP36 Q9P275 1/20 0.45
MAPT P10636 2/20 0.44
CNR2 P34972 6/20 0.43
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
EPHB4 P54760 1/20 0.43
KMT2A Q03164 1/20 0.43
CNR1 P21554 2/20 0.43
RXFP1 Q9HBX9 1/20 0.43
KIF11 P52732 1/20 0.42
PTPRC P08575 1/20 0.42
PTPN2 P17706 1/20 0.42
PTPN1 P18031 1/20 0.42
PTPRB P23467 1/20 0.42
PTPRE P23469 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5459377 0.88 CFTR (0.60) CFTRFLT3ANO1USP36MAPT
SCHEMBL5459985 0.88 CFTR (0.57) CFTRFLT3ANO1USP36MAPT
SCHEMBL5459776 0.86 FLT3 (0.66) CFTRFLT3MAPTMEN1NPC1
SCHEMBL5451652 0.84 CFTR (0.60) CFTRFLT3ANO1MAPTCNR2
SCHEMBL5453512 0.84 FLT3 (0.50) FLT3MAPTNPC1RAB9ARXFP1
SCHEMBL5458021 0.83 CFTR (0.58) CFTRFLT3ANO1CNR2MEN1
SCHEMBL5458411 0.82 CFTR (0.55) CFTRFLT3USP36MAPTCNR2
SCHEMBL5456106 0.81 CFTR (0.58) CFTRFLT3ANO1MAPTCNR2
SCHEMBL5449672 0.80 CFTR (0.55) CFTRANO1MAPTMEN1NPC1
SCHEMBL5450840 0.80 CFTR (0.54) CFTRFLT3ANO1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 CFTR 2030/4885FLT3 3509/4885ANO1 3245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.